Arthritic Therapeutic Market By Product Type (Non-steroidal Anti-inflammatory Drugs, Disease Modified Anti-rheumatoid Drugs, Biologics, Others), By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The arthritic therapeutic market was valued at $79.5 billion in 2022 and is estimated to reach $136.1 billion by 2032, exhibiting a CAGR of 5.5% from 2023 to 2032. Arthritis therapeutics involves a comprehensive array of medical interventions aimed at alleviating symptoms and managing various forms of arthritis, such as osteoarthritis and rheumatoid arthritis. These therapeutic approaches include pharmaceuticals, biologics, and lifestyle modifications tailored to mitigate pain, reduce inflammation, and enhance joint function. The goal is to improve the overall quality of life for individuals affected by arthritis, addressing the unique challenges posed by joint-related ailments. Arthritis therapeutics reflects a dynamic field that integrates medical advancements, personalized treatment strategies, and innovative solutions to provide effective relief and enhance the long-term well-being of those suffering with arthritis conditions.

The growing prevalence of arthritis conditions, including osteoarthritis, psoriatic arthritis, and rheumatoid arthritis, serves as a significant driver fueling the growth of the arthritic therapeutic market. According to the Center for Disease Control and Prevention (CDC), over 47 million Americans are affected by arthritis, with osteoarthritis impacting approximately 30.8 million individuals and rheumatoid arthritis affecting 1.3 million. This escalating prevalence underscores the pressing need for effective therapeutic interventions to manage symptoms, alleviate pain, and improve joint function. As the prevalence of arthritis conditions continues to rise, the demand for arthritis therapeutics is propelled, leading to a surge in research, development, and innovation within the pharmaceutical industry. Healthcare providers and policymakers increasingly recognize the importance of addressing the growing burden of arthritis, driving investments and initiatives aimed at expanding access to comprehensive arthritis care and advancing treatment options to meet the evolving healthcare needs of affected individuals.

In addition, the growth of the arthritic therapeutic market is propelled by a surge in R&D initiatives and a multitude of drugs in the pipeline. Major players such as Pfizer and Amgen Inc. exemplify this trend. Pfizer's Dekavi, a new molecular entity in Phase 2 trials for Rheumatoid Arthritis, underscores the commitment to innovative solutions. Similarly, Amgen's ABP 654, an investigational biosimilar in Phase 3 clinical trials, demonstrates the pursuit of alternative, cost-effective therapies. These substantial investments by key pharmaceutical companies not only showcase a dedication to addressing unmet medical needs but also indicate a collective industry effort to advance therapeutic options for arthritis patients. As more promising drugs progress through clinical trials, the market is poised for growth, reflecting a positive outlook for enhanced treatment modalities and improved outcomes in arthritis management.

The arthritic therapeutic market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics and others. On the basis of application, the market is segmented into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).

The major key players that operate in the global arthritic therapeutic market are AbbVie Inc., Pfizer, Amgen Inc, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co. Ltd, Sobi Inc. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the arthritic therapeutic market analysis from 2022 to 2032 to identify the prevailing arthritic therapeutic market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the arthritic therapeutic market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global arthritic therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Disease Modified Anti-rheumatoid Drugs (DMARDs)
Biologics
Others

By Application

Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea

Key Market Players:

AbbVie Inc.
Pfizer Inc.
Amgen Inc.
Novartis AG
Jhonson & Jhonson
Viatris Inc.
Bausch Health (Storz Opthalmic Instrument)
LEO Pharma
Merck & Co., Inc.
Celltrion Inc

Product Code: A02239

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Disease Modified Anti-rheumatoid Drugs (DMARDs)
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Biologics
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Rheumatoid Arthritis
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Osteoarthritis
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Psoriatic Arthritis
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Ankylosing Spondylitis
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Others
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country

CHAPTER 6: ARTHRITIC THERAPEUTIC MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Product Type
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Product Type
  - 6.2.4.1.2. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Product Type
  - 6.2.4.2.2. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Product Type
  - 6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Product Type
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Product Type
  - 6.3.4.1.2. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Product Type
  - 6.3.4.2.2. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Product Type
  - 6.3.4.3.2. Market size and forecast, by Application
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Product Type
  - 6.3.4.4.2. Market size and forecast, by Application
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Product Type
  - 6.3.4.5.2. Market size and forecast, by Application
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Product Type
  - 6.3.4.6.2. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Product Type
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Market size and forecast, by Product Type
  - 6.4.4.1.2. Market size and forecast, by Application
  - 6.4.4.2. China
  - 6.4.4.2.1. Market size and forecast, by Product Type
  - 6.4.4.2.2. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Market size and forecast, by Product Type
  - 6.4.4.3.2. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Market size and forecast, by Product Type
  - 6.4.4.4.2. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Product Type
  - 6.4.4.5.2. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Product Type
  - 6.4.4.6.2. Market size and forecast, by Application
6.5. Latin America
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Product Type
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Product Type
  - 6.5.4.1.2. Market size and forecast, by Application
  - 6.5.4.2. Colombia
  - 6.5.4.2.1. Market size and forecast, by Product Type
  - 6.5.4.2.2. Market size and forecast, by Application
  - 6.5.4.3. Argentina
  - 6.5.4.3.1. Market size and forecast, by Product Type
  - 6.5.4.3.2. Market size and forecast, by Application
  - 6.5.4.4. Rest Of La
  - 6.5.4.4.1. Market size and forecast, by Product Type
  - 6.5.4.4.2. Market size and forecast, by Application
6.6. Middle East and Africa
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by Product Type
- 6.6.3. Market size and forecast, by Application
- 6.6.4. Market size and forecast, by country
  - 6.6.4.1. Gcc
  - 6.6.4.1.1. Market size and forecast, by Product Type
  - 6.6.4.1.2. Market size and forecast, by Application
  - 6.6.4.2. South Africa
  - 6.6.4.2.1. Market size and forecast, by Product Type
  - 6.6.4.2.2. Market size and forecast, by Application
  - 6.6.4.3. North Africa
  - 6.6.4.3.1. Market size and forecast, by Product Type
  - 6.6.4.3.2. Market size and forecast, by Application
  - 6.6.4.4. Rest Of Mea
  - 6.6.4.4.1. Market size and forecast, by Product Type
  - 6.6.4.4.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
8.2. Pfizer Inc.
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. Amgen Inc.
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
8.4. Novartis AG
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. Jhonson & Jhonson
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Viatris Inc.
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. Bausch Health (Storz Opthalmic Instrument)
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
8.8. LEO Pharma
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
8.9. Merck & Co., Inc.
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.9.7. Key strategic moves and developments
8.10. Celltrion Inc
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments